Immunordic ApS: Financial statements 2024
CVR: 43773070
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Immunordic ApS (CVR 43773070) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 955,745 and a net result of DKK 7,762 compared with DKK -48,678 the year before. That is an increase of 76.8% compared with the year before. Equity in the 2024 report amounted to DKK 899,084. The solvency ratio was 24.9%. The company had 3 employees in the financial year.
- Gross Profit
- DKK 955,745
- Profit/Loss
- DKK 7,762
- Equity
- DKK 899,084
- Total Assets
- DKK 3,605,620
- Employees
- 3
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | 956 t. | 8 t. | 899 t. | 3 |
| 2023 | - | 541 t. | -49 t. | -9 t. | 2 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
On November 1, 2024, the company changed its name from Synobody ApS to Immunordic ApS.
Immunordic ApS has published its annual report for 2023. Gross profit came to DKK 540,638, and the net result was DKK -48,678.
About Immunordic ApS
Immunordic ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2023. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Synobody ApS. The management consists of Emil Arvedsen and Jannik Faliu. The company is owned by Arvedsen & Faliu Holding ApS. According to the 2025 annual report, the company had an average of 5 employees. In 2025, the company reported a gross profit of DKK 2,352,263 and a net result of DKK -292,800 compared with DKK 7,762 the year before. Equity in the 2025 report amounted to DKK 606,284.